learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
5 / 26 resultslearn Overview
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Saw Palmetto
a natural and far less effective alternative to Finasteride
learn GT20029
research compound made to degrade androgen receptors in scalp
Research
5 / 1000+ results
research Discussion of 'A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III' by Andrew G. Chapple and Peter F. Thall
The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.
research Tolerability of Hair Cleansing Conditioners: A Double-Blind Randomized Controlled Trial Evaluating Consumer Complaints to the U.S. Food and Drug Administration
Wen by Chaz Dean Sweet Almond Mint Cleansing Conditioner is better tolerated than salicylic acid and baby shampoos.
research The BJUI's Clinical Trials Initiative
The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.
research Evaluating Statistics in Clinical Trials: Making the Unintelligible Intelligible
Doctors need to understand statistics to properly evaluate clinical trials for patient care.
research Select the Most Correct Answers – Multiple Answers Possible for Questions 1–11
Medical practitioners need to understand basic statistics to properly evaluate clinical trials and avoid unethical designs.
Community Join
5 / 820 resultscommunity Hope Medicine HMI-115 got 28M$ investment
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
community Update about Hair Follicle Glucose Metabolism: New Clinical Data Collection with Ex-President Of American Board Of Hair Restoration Surgery.
David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.
community Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.